Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Cervantes

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
Carcinogenesis|July 7, 2016
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patientsFrancesco Sclafani, Ian Chau, David Cunningham, et al.
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2021
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of RecurrencesTenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid TumorsIgnacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid TumorsDidier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
Nature Medicine|April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trialDevalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 2, 2022
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancerTiuri E Kroese, Peter S N van Rossum, Magnus Nilsson, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
Carcinogenesis|July 7, 2016
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patientsFrancesco Sclafani, Ian Chau, David Cunningham, et al.
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2021
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of RecurrencesTenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid TumorsIgnacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid TumorsDidier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
Nature Medicine|April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trialDevalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 2, 2022
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancerTiuri E Kroese, Peter S N van Rossum, Magnus Nilsson, et al.
Pageof 8